Well-known examples include trastuzumab (Herceptin: Genentech Inc.; San Francisco, CA) for HER2-positive breast cancer treatment and bevacizumab (Avastin: Genentech Inc.)that binds to vascular endothelial growth factor. Here, VEGFA is linked to breast carcinoma.